X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NOVARTIS - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NOVARTIS FRESENIUS KABI ONCO./
NOVARTIS
 
P/E (TTM) x 22.1 265.2 8.3% View Chart
P/BV x 3.1 22.6 13.8% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 FRESENIUS KABI ONCO.   NOVARTIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NOVARTIS
Mar-17
FRESENIUS KABI ONCO./
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs176855 20.6%   
Low Rs79666 11.8%   
Sales per share (Unadj.) Rs37.7219.0 17.2%  
Earnings per share (Unadj.) Rs5.119.1 26.7%  
Cash flow per share (Unadj.) Rs6.720.3 33.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs42.5307.0 13.9%  
Shares outstanding (eoy) m158.2329.96 528.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.5 97.3%   
Avg P/E ratio x25.039.8 62.8%  
P/CF ratio (eoy) x18.937.5 50.5%  
Price / Book Value ratio x3.02.5 120.8%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m20,13522,779 88.4%   
No. of employees `0001.20.7 170.9%   
Total wages/salary Rs m7031,393 50.5%   
Avg. sales/employee Rs Th5,176.29,736.2 53.2%   
Avg. wages/employee Rs Th610.42,066.8 29.5%   
Avg. net profit/employee Rs Th699.6849.0 82.4%   
INCOME DATA
Net Sales Rs m5,9636,562 90.9%  
Other income Rs m18702 2.6%   
Total revenues Rs m5,9817,264 82.3%   
Gross profit Rs m1,430259 552.4%  
Depreciation Rs m25836 718.4%   
Interest Rs m-267 -361.1%   
Profit before tax Rs m1,216917 132.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342345 99.2%   
Profit after tax Rs m806572 140.8%  
Gross profit margin %24.03.9 607.9%  
Effective tax rate %28.137.6 74.8%   
Net profit margin %13.58.7 155.0%  
BALANCE SHEET DATA
Current assets Rs m5,1029,731 52.4%   
Current liabilities Rs m2,3851,830 130.3%   
Net working cap to sales %45.6120.4 37.8%  
Current ratio x2.15.3 40.2%  
Inventory Days Days15049 308.2%  
Debtors Days Days11325 450.3%  
Net fixed assets Rs m5,14857 9,000.2%   
Share capital Rs m158141 112.4%   
"Free" reserves Rs m6,5569,056 72.4%   
Net worth Rs m6,7329,196 73.2%   
Long term debt Rs m9520-   
Total assets Rs m10,38811,499 90.3%  
Interest coverage x-45.8128.4 -35.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 100.6%   
Return on assets %7.55.0 149.0%  
Return on equity %12.06.2 192.4%  
Return on capital %14.610.1 145.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298129 4,109.9%   
Fx outflow Rs m1,7721,734 102.2%   
Net fx Rs m3,525-1,605 -219.7%   
CASH FLOW
From Operations Rs m1,274-380 -335.7%  
From Investments Rs m-1,2044,208 -28.6%  
From Financial Activity Rs m-196-3,318 5.9%  
Net Cashflow Rs m-126510 -24.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 9.6 1.6 600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   42,599 41,647 102.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALKEM LABORATORIES  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; SBI Up 3.7%(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SHASUN PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS